Advertisement

Breast Cancer Research and Treatment

, Volume 126, Issue 2, pp 421–430 | Cite as

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

  • Mahmoud R. KhoshnoudEmail author
  • Britta Löfdahl
  • Helena Fohlin
  • Tommy Fornander
  • Olle Stål
  • Lambert Skoog
  • Jonas Bergh
  • Bo Nordenskjöld
Clinical trial

Abstract

The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomized trial during 1976 through 1990 comparing adjuvant tamoxifen versus control. The patients were stratified according to tumor size and lymph node status in high-risk and low-risk groups. In this study we evaluated 683 patients with “low risk” breast cancer (size ≤30 mm, lymph node-negative) for whom ER status had been determined by both the cytosol assays and IHC at one pathology laboratory. The median follow-up was 17 years. Six hundred eighty-three patients had tumors with ER determined by both methods, 536 (78.5%) were ER-positive by cytosol assays using the cutoff level at ≥0.05 fmol/μg DNA and 539 patients were ER-positive (79%) by IHC using the cutoff level at ≥10% cell stained. Thirty-nine tumors (5.7%) were ER-positive by cytosol but not by IHC, whereas the opposite pattern was found for 42 cases (6.1%). Only seven tumors had stained cells between 0 and 9% by IHC. The concordance between IHC and cytosol assays was high (88%). The kappa statistic was 0.65, 95% CI 0.58–0.72. Among patients classified as ER-negative no therapeutic benefit from tamoxifen was observed. Among patients with ER-expressing tumors, tamoxifen resulted in significantly better recurrence-free survival irrespective of the method (IHC: HR, 0.53, P < 0.001; cytosol: HR, 0.53, P < 0.001). The effect on overall survival was not statistically significant probably due to the limited sample size. Both IHC and cytosol assay accurately predict long-term response to adjuvant tamoxifen.

Keywords

Breast cancer Estrogen receptor Tamoxifen Cytosol Immunohistochemical 

Notes

Acknowledgments

This research was supported by grants from the Swedish Cancer Society and the Swedish Research Council to Olle Stål and Jonas Bergh and funds of Jonas Bergh’s Research Group at Radiumhemmet and the Stockholm County Council.

References

  1. 1.
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21(17):3357–3365PubMedCrossRefGoogle Scholar
  2. 2.
    McGuire WL (1980) An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli S et al (eds) Hormones and cancer. Raven Press, New YorkGoogle Scholar
  3. 3.
    Group EBCTC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467CrossRefGoogle Scholar
  4. 4.
    Crowe JP Jr, Gordon NH, Hubay CA, Shenk RR, Zollinger RM, Brumberg DJ, McGuire WL, Shuck JM (1991) Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 173(4):273–278PubMedGoogle Scholar
  5. 5.
    Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K (1978) Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38(11 Pt 2):4292–4295PubMedGoogle Scholar
  6. 6.
    Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669–4671PubMedGoogle Scholar
  7. 7.
    Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A (1984) Estrogen receptors and long-term prognosis in breast cancer. Cancer 53(11):2525–2529PubMedCrossRefGoogle Scholar
  8. 8.
    Donegan WL (1992) Prognostic factors. Stage and receptor status in breast cancer. Cancer 70(6 Suppl):1755–1764PubMedCrossRefGoogle Scholar
  9. 9.
    Early Breast Cancer Trialist’s Collaborative Group (2005) Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-years survival: an overview of the randomised trials. Lancet 365:1687–1717Google Scholar
  10. 10.
    Khoshnoud MR, Fornander T, Johansson H, Rutqvist LE (2008) Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen. Breast Cancer Res Treat 107(1):71–78PubMedCrossRefGoogle Scholar
  11. 11.
    Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66(8):1663–1670PubMedCrossRefGoogle Scholar
  12. 12.
    Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J, Tuchler H (1998) Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: evaluation of discordant findings. Breast Cancer Res Treat 50(2):125–134PubMedCrossRefGoogle Scholar
  13. 13.
    Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelenat H, Sastre-Garau X (2000) High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37(6):536–545PubMedCrossRefGoogle Scholar
  14. 14.
    Chebil G, Bendahl PO, Idvall I, Ferno M (2003) Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer—clinical associations and reasons for discrepancies. Acta Oncol 42(7):719–725PubMedCrossRefGoogle Scholar
  15. 15.
    Beck T, Weikel W, Brumm C, Wilkens C, Pollow K, Knapstein PG (1994) Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 53(2):220–227PubMedCrossRefGoogle Scholar
  16. 16.
    Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spagnolli P, Manfrin E et al (1997) Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45(3):241–249PubMedCrossRefGoogle Scholar
  17. 17.
    Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, Pritchard J, Pereira T, Geyer C, Wolmark N (2005) Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 103(1):164–173PubMedCrossRefGoogle Scholar
  18. 18.
    Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, Krook JE, Wieand HS (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78(4):764–772PubMedCrossRefGoogle Scholar
  19. 19.
    Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L et al (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98(21):1571–1581PubMedCrossRefGoogle Scholar
  20. 20.
    Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, Somell A, Theve T, Friberg S, Askergren J (1987) The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10(3):255–266PubMedCrossRefGoogle Scholar
  21. 21.
    Wrange O, Nordenskjold B, Silfversward C, Granberg PO, Gustafsson JA (1976) Isoelectric focusing of estradiol receptor protein from human mammary carcinoma—a comparison to sucrose gradient analysis. Eur J Cancer 12(9):695–700PubMedGoogle Scholar
  22. 22.
    Wrange O, Nordenskjold B, Gustafsson JA (1978) Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85(2):461–475PubMedCrossRefGoogle Scholar
  23. 23.
    Ferno M, Borg A, Norgren A (1983) A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3(4):243–246PubMedGoogle Scholar
  24. 24.
    Ferno M, Borg A, Sellberg G (1986) Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25(3):171–175PubMedCrossRefGoogle Scholar
  25. 25.
    Burton K (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62(2):315–323PubMedGoogle Scholar
  26. 26.
    Bonetti M, Bonetti M, Gelber RD (2000) A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19(19):2595–2609PubMedCrossRefGoogle Scholar
  27. 27.
    Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC et al (1983) Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2(8347):450PubMedCrossRefGoogle Scholar
  28. 28.
    Stewart HJ, Prescott R (1985) Adjuvant tamoxifen therapy and receptor levels. Lancet 1(8428):573PubMedCrossRefGoogle Scholar
  29. 29.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85Google Scholar
  30. 30.
    Ferno M, Andersson C, Fallenius G, Idvall I (1996) Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol 35(1):17–22PubMedCrossRefGoogle Scholar
  31. 31.
    Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481PubMedGoogle Scholar
  32. 32.
    Rutqvist LE, Johansson H (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46(2):133–145PubMedCrossRefGoogle Scholar
  33. 33.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795PubMedCrossRefGoogle Scholar
  34. 34.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25(25):3846–3852PubMedCrossRefGoogle Scholar
  35. 35.
    Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Mahmoud R. Khoshnoud
    • 1
    Email author
  • Britta Löfdahl
    • 2
  • Helena Fohlin
    • 3
  • Tommy Fornander
    • 1
  • Olle Stål
    • 4
  • Lambert Skoog
    • 5
  • Jonas Bergh
    • 6
    • 7
  • Bo Nordenskjöld
    • 4
  1. 1.Department of Oncology, Karolinska University HospitalKarolinska InstituteStockholmSweden
  2. 2.Department of PathologyUppsala University HospitalUppsalaSweden
  3. 3.Oncology CentreLinköping University HospitalLinköpingSweden
  4. 4.Department of Clinical and Experimental Medicine/Oncology, Faculty of Health SciencesLinköping UniversityLinköpingSweden
  5. 5.Department of Pathology, Karolinska University HospitalKarolinska InstituteStockholmSweden
  6. 6.Cancer Center KarolinskaKarolinska InstituteStockholmSweden
  7. 7.Medical Breast Unit, Christie HospitalPaterson Institute/Manchester UniversityManchesterUK

Personalised recommendations